A phase II study to evaluate ZD1839 (Iressa) in second line combination with paclitaxel (taxol) and carboplatin (paraplatin) in patients with advanced ovarian, peritoneal or fallopian tube adenocarcinoma
Study identifier:1839IL/0074
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A phase II study to evaluate ZD1839 (Iressa) in second line combination with paclitaxel (taxol) and carboplatin (paraplatin) in patients with advanced ovarian, peritoneal or fallopian tube adenocarcinoma
Medical condition
cancer
Phase
Phase 2
Healthy volunteers
-
Study drug
-
Sex
-
Actual Enrollment
-
Study type
Interventional
Age
-
Date
Study Start Date: 01 Mar 2002
Primary Completion Date: -
Study Completion Date: -
Study design
Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -
Verification:
Verified 01 Nov 2013 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
